Futility analysis leads to another CGRP setback for Teva

Israeli generics giant Teva Pharmaceutical (NYSE: TEVA) says it is scrapping its clinical development program for its calcitonin gene-related peptide (CGRP) blocker fremanezumab (trade name Ajovy) in episodic cluster headaches.

The decision, prompted by a futility analysis of the Phase III ENFORCE study, comes less than a year after Teva dropped development of the biologic for chronic cluster headaches.

The firm’s data show the study’s primary endpoint, a reduction in headache attacks during the four-week treatment period, is unlikely to be met.